Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358439 | 0.86 | KMT2A (0.71) | ALDH1A1KMT2AMAPK1L3MBTL1BCHE | |
| SCHEMBL12205239 | 0.76 | ALDH1A1 (0.64) | ALDH1A1KMT2ARECQLHTTPOLB | |
| Bromide SCHEMBL7514295 | 0.75 | ALDH1A1 (0.76) | ALDH1A1KMT2ARECQLHTTMEN1 | |
| SCHEMBL5367456 | 0.74 | ALDH1A1 (0.56) | ALDH1A1KMT2ARECQLHTTPOLB | |
| SCHEMBL10307403 | 0.72 | ALDH1A1 (0.59) | ALDH1A1RECQLHTTPOLBHSP90AA1 | |
| SCHEMBL5445229 | 0.70 | ALDH1A1 (0.57) | ALDH1A1KMT2ARECQLHTTPOLB | |
| SCHEMBL10307413 | 0.70 | ALDH1A1 (0.57) | ALDH1A1RECQLHTTPOLBHSP90AA1 | |
| SCHEMBL3841660 | 0.70 | ALDH1A1 (0.57) | ALDH1A1RECQLHTTHSP90AA1GLA | |
| Bromide SCHEMBL9155378 | 0.70 | NPSR1 (0.62) | ALDH1A1KMT2AL3MBTL1BCHEACHE | |
| SCHEMBL28089629 | 0.70 | TSHR (0.68) | ALDH1A1KMT2AMAPK1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| EP-1689714-A2 | THERAPEUTIC USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054198-A2 | THERAPEUTICS USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105810-A1 | THERAPEUTICS | RYR1, ATP2A1, CACNA1E | ALDH1A1 2886/4885KMT2A 3979/4885MAPK1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.